Repotrectinib Overcomes F2004V Resistance Mutation in ROS1-Rearranged NSCLC: A Case Report

ROS1 tyrosine kinase inhibitors (TKIs) were found to provide a substantial clinical benefit for patients with advanced ROS1-positive (ROS1+) NSCLC. Nevertheless, TKI resistance inevitably develops with different mechanisms, preventing prolonged responses. For this reason, next-generation compounds a...

Descripción completa

Detalles Bibliográficos
Autores principales: Pizzutilo, Elio Gregory, Agostara, Alberto Giuseppe, Roazzi, Laura, Romanò, Rebecca, Motta, Valentina, Lauricella, Calogero, Marrapese, Giovanna, Cerea, Giulio, Signorelli, Diego, Veronese, Silvio Marco, Giannetta, Laura Giuseppina, Sartore-Bianchi, Andrea, Siena, Salvatore
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10689265/
https://www.ncbi.nlm.nih.gov/pubmed/38047274
http://dx.doi.org/10.1016/j.jtocrr.2023.100555

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10689265/
https://www.ncbi.nlm.nih.gov/pubmed/38047274
http://dx.doi.org/10.1016/j.jtocrr.2023.100555

Ejemplares similares